3 Growth Stocks That Are Crushing It This Year
The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months. Contrast that with Vertex Pharmaceuticals (NASDAQ: VRTX), Axsome Therapeutics (NASDAQ: AXSM), and Neurocrine Biosciences (NASDAQ: NBIX), as all are up 20% or more this year.